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Abstract 
Cancer stem cells are an attractive target for immunotherapeutic approaches to 
glioblastoma. However, an immune inhibitory phenotype of cells currently classified 
as “glioma-initiating cells” (GIC) might counteract recognition by immune effector 
cells. Here, we investigate the contribution of the non-classical MHC molecule HLA-E 
to the immunosuppressive phenotype of GIC. HLA-E is expressed in GIC lines and 
its expression is reduced upon differentiation of GIC in serum-containing culture 
conditions. Constitutive HLA-E inhibits natural killer (NK) cell-mediated lysis of GIC 
since small-interfering RNA-mediated HLA-E gene silencing enhances the 
immunogenicity of GIC. Increased GIC lysis was observed both in the CD133+ and in 
the CD133- compartment. Furthermore, the use of interferon-γ as a possible agent to 
boost an immune response against glioblastoma cells might be limited by the 
concurrent upregulation of HLA-E. 
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1. Introduction  
Considering the poor prognosis of patients with glioblastoma, there is a need for new 
therapies beyond surgery, radiotherapy and chemotherapy. Immunotherapy has 
been considered a promising alternative to treat this devastating disease. However, 
to date, the clinical results of immunotherapeutic strategies in glioblastoma have 
remained disappointing. This lack of  efficacy might be related to immune inhibitory 
properties of glioblastoma cells facilitating immune evasion (Heimberger and 
Sampson, 2011). Glioma cells should per se be prone to attack by immune effector 
cells since they express ligands for activating immune receptors on NK cells or 
cytotoxic T cells (Dietrich et al., 2011; Eisele et al., 2006; Friese et al., 2003; Friese et 
al., 2004; Wischhusen et al., 2005). However, an immunosuppressive micromilieu 
hampers an efficient immune response. The cytokine transforming growth factor 
(TGF)-ß contributes largely to this immunosuppression by multiple mechanisms, 
including upregulation of the inhibitory receptor CD94/NKG2A on immune effector 
cells (Bertone et al., 1999). This heterodimeric receptor consisting of CD94 and either 
NKG2A or its splice variant NKG2C is expressed on the cell surface of NK cells as 
well as CD8+ αβ and γδ T cells (Pietra et al., 2009). The binding of CD94/NKG2A to 
its ligand, the atypical human leukocyte antigen (HLA-)-E leads to phosphorylation of 
immunoreceptor tyrosine based inhibitory motifs (ITIMS) in the intracytoplasmatic 
domain of NKG2A and thus to inhibition of the lytic activity of NK cells. Conversely, 
the binding of CD94/NKG2C to HLA-E provides an activating signal, however NKG2C 
binds HLA-E with low affinity and is therefore thought to play a subordinate role 
(Wada et al., 2004). Under physiological conditions, HLA-E is mainly involved in 
maternal immune tolerance. HLA-E is abberantly expressed in several tumors like 
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lymphoma (Marin et al., 2003), melanoma (Derre et al., 2006), colon carcinoma 
(Bianchini et al., 2006), ovarian cancer (Malmberg et al., 2002) and may contribute to 
immunosuppression in glioblastoma (Mittelbronn et al., 2007; Wischhusen et al., 
2005).  
A crucial issue for effective cancer immunotherapy is the definition of the target. In 
this regard of special interest are cells within glioblastomas with stem cell-like 
properties. GIC are defined by their stem cell properties of self-renewal, multipotency 
and tumorigenicity at low cell numbers in immunodeficient mice, forming tumors 
resembling the initial human tumors (Singh et al., 2004; Tabatabai and Weller, 2011). 
In a hierarchical tumor model, GIC are supposed to have important functions in the 
initiation and maintenance of glioblastomas and therefore warrant being evaluated as 
a possible target for immunotherapy. GIC can be isolated from gliomas ex vivo and 
propagated under serum-free stem cell culture conditions including fibroblast and 
epidermal growth factor (Gunther et al., 2008; Hemmati et al., 2003). Other 
approaches to isolate GIC use functional assays or cell surface markers like CD133 
(Tabatabai and Weller, 2011). CD133, or prominin-1, a cholesterol binding molecule 
of unknown biological function, was initially introduced as a putative cell surface 
marker for GIC (Singh et al., 2004) and is still widely used. However, the role of 
CD133 in identifying GIC remains controverseial and is challenged by the 
characterisation of CD133 negative glioblastoma cells with stem cell properties (Beier 
and Beier, 2011) or the upregulation of CD133 under hypoxic culture conditions or 
cellular stress (Bar et al., 2010; Griguer et al., 2008). 
Here, we investigate the possible contribution of HLA-E to the immune inhibitory 
phenotype of GIC in a set of previously characterized GIC lines, cultured under stem 
cell conditions and harbouring the stemness properties of self-renewal, multipotency 
and tumorigenicity in vivo (Gunther et al., 2008). We find cell surface expression of 
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HLA-E in 4 out of 5 cell lines. HLA-E inhibits NK cell function as demonstrated by 
increased NK cell mediated cytotoxicity following RNA-mediated HLA-E gene 
silencing. HLA-E expression is increased by interferon (IFN)-γ, potentially limiting the 
usefulness of this immune stimulating cytokine in the context of immunotherapy for 
glioblastoma targeting GIC. 
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2. Materials and Methods 
Materials and Cell Lines 
The GIC lines GS-2, GS-4, GS-5, GS-7 and 9 have been characterized (Gunther et 
al., 2008): in summary, the cell lines expressed stemness markers Sox2 and nestin in 
undifferentiated GIC and either neuronal (MAP2 and neurofilament), oligodendroglial 
(galactocerebroside) or glial markers (glial fibrillary acidic protein) in their 
differentiated counterparts. Moreover, the GIC lines were characterized by self-
renewal and their tumorigenicity was confirmed in vivo. Gene expression analysis 
revealed 2 different subtypes of the GIC lines. The GIC cluster 1 (GS-5 and 9) was 
characterized by the expression of neurodevelopmental genes and a full stem-like 
phenotype and cluster 2 (GS-2, 4 and 9) by an expression signature enriched for 
extracellular matrix-related genes with a restricted stem-like phenotype. 
All GIC lines were cultured in 75cm2 culture flasks and maintained in Neurobasal 
Medium with B-27 supplement (20 µl/ml) and Glutamax (10 µl/ml) from Invitrogen 
(Basel, Switzerland) and fibroblast growth factor (FGF)-2, epidermal growth factor 
(EGF) (20 ng/ml each; Peprotech, Rocky Hill, Pennsylvania) and heparin (32 IE/ml; 
Ratiopharm, Ulm, Germany). GS-2 and GS-5 grow as sphere cultures, GS-7 and GS-
9 as semi-adherent and GS- 4 adherent under stem cell medium conditions (Figure 
1). GIC lines were differentiated by culture in Dulbecco's Modified Eagle Medium 
(DMEM; Invitrogen, Basel, Switzerland), containing 2 mM L-glutamine (Gibco Life 
Technologies, Paisley, UK), penicillin (100 IU/ml)/streptomycin (100 mg/ml) (Gibco) 
and 10% fetal calf serum (FCS; PAA, Vienna, Austria). The colon carcinoma cell line 
HT29 served as a positive control for the expression of CD133 (Ieta et al., 2008) and 
was cultured in DMEM (Invitrogen) containing 10% FCS (PAA), 2 mM L-glutamine 
(Gibco Life Technologies) and penicillin (100 IU/ml)/streptomycin (100 mg/ml) 
(Gibco). The NK cell line NKL (Robertson et al., 1996) was cultured in RPMI 1640 
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medium (PAA, Wien, Austria) containing 15% FCS, 2 mM L-glutamine (Gibco Life 
Technologies, Paisley, UK), penicillin (100 IU/ml)/streptomycin (100 mg/ml) (Gibco), 
1 mM sodium pyruvate and 50 U/ml Interleukin 2 (Peprotech). 
 
Monoclonal Antibodies and Flow Cytometry  
GIC growing as spheres were mechanically dissociated by pipetting and dissolved in 
Accutase (PAA) to get a single cell suspension. (Semi-)adherent cells were detached 
using Accutase. Cell surface expression was assessed with the following monoclonal 
antibodies (mAbs): anti-HLA-E (clone 3D12; purified and conjugated 
(allophycocyanine; APC);  mouse IgG1, eBioscience, Vienna, Austria), anti-MHC-I 
and anti-HLA-G (clone W6/32 and 87G respectively; mouse IgG2a, Biologend, 
Uithoorn, Netherlands), anti-CD133 (clone AC133; PE-conjugated; mouse IgG1, 
Miltenyi Biotec, Bergisch Gladbach, Germany). Unconjugated IgG1 (clone MOPC 21; 
Sigma-Aldrich, Buchs, Switzerland) and IgG2a (clone MOPC-173; Biologend) or 
conjugated IgG1 (clone MOPC 21; PE-conjugated, Sigma-Aldrich) and IgG1 (clone 
P3.6.2.8.1; APC-conjugated, eBioscience) isotype-matched mAbs were used as 
controls. The PE-conjugated goat anti-mouse IgG (dilution 1:20) (Dako, Freiburg, 
Germany) was used as secondary antibody where appropriate. The cells were 
preincubated in PBS with 2% FCS and stained with specific mAb or matched mouse 
Ig isotype for 30 min on ice, followed by incubation with the PE-conjugated secondary 
antibody for 30 min where appropriate. Then the cells were washed with PBS 
containing 2% FCS. For the detection of HLA-E on CD133-expressing cells, the GIC 
were double-stained with PE-conjugated anti-CD133 and APC-conjugated anti-HLA-
E antibody or matching isotype controls respectively. Flow cytometry was performed 
with a CyAn ADP Analyzer (Beckman Coulter, Nyon, Switzerland). Specific 
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fluorescence indices (SFI) were calculated by dividing median fluorescence obtained 
with the specific antibody by median fluorescence obtained with the control antibody.  
Following staining with PE-conjugated anti-CD133 mAb, GS-2 cells were separated 
by fluorescence activated cell sorting (FACS) using the FACSAria III and FACSDiva 
software (both Becton Dickinson, San Diego, CA) for the presence or absence of 
CD133 on the cell surface. The purity of the sorted cells was ascertained by 
subsequent analysis by flow cytometry using a CyAn ADP Analyzer (Beckman 
Coulter). 
 
Real-Time PCR 
RNA was prepared from the cell lines using NucleoSpin RNA II Kit (Macherey-Nagel, 
Düren, Germany). Subsequently, cDNA was generated using SuperScript II Reverse 
Transcriptase (Invitrogen AG, Basel, Switzerland). RNA and DNA concentrations 
were determined using NanoDrop (Thermo Scientific, Waltham, Massachusetts). 
cDNA amplification was monitored using SYBRGreen chemistry on the ABI 
PRISM7000 Sequence Detection System (Applied Bio-Systems, Weiterstadt, 
Germany) using the following specific primers (forward/reverse): GAPDH: 5’-
CTCTCTGCTCCTCCTGTTCGAC-3’ (450-469), 5’-TGAGCGATGTGGCTCGGCT-3’ 
(636-619); HLA-E: 5’-GGGACACCGCACAGATTTT-3’ (266-284), 5’CTCA-
GAGGCATCATTTGACTTTT (519-497) (Wischhusen et al., 2005). Data analysis was 
done using the DDCT method for relative quantification. Briefly, threshold cycles (CT) 
for GAPDH RNA (reference) and HLA-E (sample) were determined in duplicate. The 
expression levels were determined following the formula: rI=2-[CTHLA-E - CT GAPDH].  
 
RNA interference 
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To silence HLA-E expression, the glioma cells were transiently transfected with 
siRNA targeting specifically HLA-E (Wischhusen et al., 2005): (535-553): 5’-
GCCUACCUGGAAGACACAU(dTdT)-3’ and 5’AUGUGUCUUCCAGGUAGGC(dTdT) 
-3’. ON-TARGETplus Non-Targeting Pool siRNA (Dharmacon, Lafayette, Colorado) 
was used as negative control. Glioma cells were seeded in 6 cm plates over night 
and subsequently transfected with siRNA using Metafectene Pro (Biontex, 
Martinsried, Germany). Gene silencing was verified by flow cytometry at various time 
points after transfection. 
 
Cytotoxicity assay 
We used a flow cytometry-based cytotoxicity assay (Lee-MacAry et al., 2001) which 
employs the membrane dye PKH-26 and the viability dye ToPro3. This assay is 
widely used as a system to determine NK or T cell-mediated cytotoxicity. The target 
cells were stained with PKH-26 membrane dye. This enables the discrimination of the 
target cells from the effector cells in the subsequent lysis assay.  Briefly, the target 
cells were incubated with PKH-26 dissolved in Diluent C (1:250; all from Sigma–
Aldrich) for 3 min. Staining was stopped by washing with RPMI 1640 medium 
containing 10% FCS. Then the effector and target cells were coincubated at varying 
effector to target (E:T) ratios for 3 h. Immediately prior to flow cytometry, the viability 
dye ToPro3 (Invitrogen) was added. The percentage of target cell lysis was 
determined by flow cytometry using the CyAn ADP Analyzer (Beckman Coulter). 
Specific lysis was assessed by subtraction of background lysis. 
 
Statistical analysis 
The experiments were performed 2 to 3 times as indicated. Statistical significance 
was calculated by student`s two-tailed t-test where indicated (* p<0.05; ** p<0.01). 
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3. Results 
GIC express HLA-E 
The expression of HLA-E in the GIC lines was assessed on mRNA and protein level 
using real-time PCR and flow cytometry, both under stem cell conditions and after 
differentiation. Compared to stem cell conditions, HLA-E mRNA levels were similar or 
increased in differentiated cultures (Figure 2A). However, on the protein level, we 
found significant higher levels of cell surface HLA-E in the GIC lines GS-4, GS-5 and 
GS-7 when grown under stem cell conditions. The SFI values for HLA-E expression 
in the cell lines GS-2 and GS-9 were similar under stem cell and differentiating 
culture conditions (Figure2B) with only marginal expression of HLA-E on the surface 
of GS-9 cells. (Figure 2B and D). Figure 2D shows representative histograms 
documenting the expression of HLA-E on GIC under stem cell and differentiation 
conditions. The expression pattern of HLA-E was paralleled by a trend to elevated 
expression of MHC-I on the cell surface in GS-4, GS-5 and GS-7 under stem cell 
conditions (Figure 2C). 
 
HLA-E gene silencing in GIC enhances susceptibility towards NK-cell mediated 
lysis 
To define the role of HLA-E in immune recognition of GIC by NK cells, we used 
siRNA to transiently silence HLA-E expression in GS-2, GS-5 and GS-7 growing 
under stem cell medium conditions. The knock-down of HLA-E was confirmed by flow 
cytometry (Figure 3A). The expression level of MHC-I remained unaltered following 
HLA-E gene silencing as confirmed by flow cytometry (data not shown). Following the 
knock-down of HLA-E expression, the GS cells were then used as targets in a 
cytotoxicity assay using NKL as effector cells. The knock-down of HLA-E led to an 
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enhanced susceptibility of GIC to NK cell-mediated lysis (Figure 3B). This was also 
true for GS-7 cells growing under differentiation medium conditions (data not shown). 
 
HLA-E cell surface expression on GIC is up-regulated by IFN-γ 
Stimulation of GIC with IFN-γ (500 IU/ml) for 48 h led to enhanced expression of 
HLA-E mRNA as assessed by real-time PCR in GS-5, GS-7 and GS-9 and to a 
lesser extent in GS-2 and GS-4 (Figure 4A). Conversely, the cell surface expression 
of HLA-E protein was increased in all GS lines (Figure 4B), paralleled by an increase 
of MHC-I expression (data not shown). The upregulation of HLA-E on the cell surface 
was similar on GIC growing under stem cell or differentiation medium conditions 
except for GS-5 with a prominent increase of HLA-E following treatment under stem 
cell compared to differentiation conditions (Figure 4B).  
To assess a possible immune-inhibitory effect and to determine the net immune-
regulatory effect following stimulation of GIC with IFN-γ, the cell lines GS-5 and GS-7 
were used as targets in a cytotoxicity assay using NKL as effector cells. While IFN-γ 
had no effect on the susceptibility to NKL mediated lysis in GS-7 (Figure 4D), the lytic 
activity of NKL towards GS-5 treated with IFN-γ was reduced compared to untreated 
controls (Figure 4C). 
 
Silencing of HLA-E expression in CD133+ cells enhances susceptibility 
towards NK-cell mediated lysis 
Despite limitations, CD133 is still used as a putative cell surface marker for GIC. 
Therefore, we assessed cell surface expression of HLA-E on CD133+ and CD133- 
cells and the impact of HLA-E gene silencing on NK cell mediated lysis by absence 
or presence of CD133 in the GIC line GS-2 (Figure 5). As reported (Gunther et al., 
2008), approximately 9% of the GS-2 cells are CD133+ as assessed by flow 
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cytometry. The expression of HLA-E was similar on CD133+ and CD133- GS-2 cells 
as assessed by flow cytometry following double staining with PE-conjugated anti-
CD133 and APC-conjugated anti-HLA-E mABs (Figure 5A). The GS-2 cells were 
sorted by FACS into a CD133+ and a CD133- fraction using the FACSAria III device. 
Purity of the respective fractions was ascertained with about 95% by flow cytometry. 
Following sorting, we used siRNA to transiently silence HLA-E expression in CD133+ 
and CD133- GS-2 cells as described above. The knock-down of HLA-E was 
confirmed by flow cytometry (data not shown). Following the silencing of HLA-E 
expression, the cells were used as targets in a cytotoxicity assay using NKL as 
effector cells. The knock-down of HLA-E led to an enhanced susceptibility of GS-2 
GIC to NK cell-mediated lysis irrespective of the expression of CD133 (Figure 5B).  
To investigate a possibly differential regulation of HLA-E expression by IFN-γ, a 
fraction of the sorted cells was treated with IFN-γ (500 IU/ml for 48 h). Following 
stimulation with IFN-γ the cell surface expression of HLA-E was increased in CD133+ 
(SFI 9.4 vs. SFI 2.4 in untreated controls) and CD133- (SFI 9.7 vs. 2.3 in untreated 
controls) cells as assessed by flow cytometry.  
- 13 - 
4. Discussion  
Immunotherapeutic approaches to glioblastoma continue to attract significant 
attention, based on their localized growth in the central nervous system and the 
associated cellular immunosuppression. Recent reports have defined an immune-
inhibitory phenotype specifically of GIC (Di Tomaso et al., 2010; Wei et al., 2010a; 
Wei et al., 2010b). Here, we define a possible role of the atypical HLA molecule, 
HLA-E, for the immunosuppressive phenotype of GIC. HLA-E is expressed on the 
cell surface of all GS lines investigated here, except for GS-9 (Figure 2B). Compared 
to differentiating culture conditions, the expression of HLA-E is enhanced under stem 
cell conditions in GS-4, GS-5 and GS-7 (Figure 2B). The cell surface expression of 
HLA-E under stem cell compared to differentiating conditions is not reflected at the 
level of mRNA expression (Figure 2A and B). Therefore, other mechanisms 
regulating HLA-E expression on GIC seem to be involved. Similar to classical MHC 
class-I molecules, the expression of HLA-E depends on efficient peptide loading 
leading to the assembly of a trimeric complex including beta2-microglobulin and 
subsequent translocation to the cell membrane (Ulbrecht et al., 1999). This process 
can be compromised in tumor cells, leading to differences between HLA-E mRNA 
and cell surface expression levels of HLA-E (Palmisano et al., 2005). Moreover, 
metalloproteinase-dependent shedding of HLA-E occurs in tumor cells (Derre et al., 
2006). Therefore, the expression of HLA-E on the cell surface in GIC might be under 
the control of complex post-translational regulation.  
The immunosuppressive mechanisms of GIC include induction of regulatory T cells, 
inhibition of proliferation and apoptosis of T cells in vitro with B7-H1 and soluble 
galectin-3. These immunosuppressive functions of GIC seem to depend on the 
constitutive activation of the STAT-3 pathway, a potent anti-inflammatory regulatory 
pathway (Wei et al., 2010a). Moreover, a defective antigen processing machinery in 
- 14 - 
GIC underscores their ability to evade a T cell-mediated immune response (Di 
Tomaso et al., 2010). However, GIC can not entirely hide from immune effector cells 
since they can be attacked by NK cells via the activating receptors NKp46, DNAM-I 
or to a lesser extent NKG2D in vitro (Castriconi et al., 2009; Di Tomaso et al., 2010), 
a process which might be counteracted by HLA-E.  
Here, we provide evidence that HLA-E hampers indeed NK cell-mediated immune 
recognition of GIC as demonstrated by siRNA-mediated gene silencing (Figure 3B, 
5B), thus contributing to the immunosuppressive phenotype of GIC. These results are 
consistent with the role of HLA-E in counteracting NK cell-mediated cytotoxicity 
towards human glioma cell lines (Wischhusen et al., 2005). 
The role of HLA-E in the regulation of anti-tumor immune responses is mainly 
investigated in the context of innate immunity given the predominant expression of 
the receptors NKG2A and NKG2C on NK cells. However, these receptors are also 
expressed on a subset of cytotoxic T lymphocytes (Arlettaz et al., 2004). Little is 
known about interactions of HLA-E with T lymphocytes in glioblastoma. The 
correlation of HLA-E expression levels with the extent of infiltration by CD8+ T cells in 
human glioblastoma might be explained with an IFN-γ induced upregulation of HLA-E 
(Mittelbronn et al., 2007). However, restrained function of tumor-infiltrating CD8+ T 
lymphocytes as a consequence of tumor-associated expression of HLA-E has been 
demonstrated in ovarian cancer (Gooden et al., 2011). Moreover, HLA-E can bind 
and present viral or bacterial peptides and interact directly with the T cell receptor of 
HLA-E restricted CD8+ T cell subsets, thus regulating adaptive immunity against 
infectious pathogens (Pietra et al., 2003; Schulte et al., 2009). However, the role of 
this mechanism in tumor immunity is yet not clear. Peptides derived from isoforms of 
peroxiredoxin 5, occurring in a melanoma cell line, were recognized by CD8+ HLA-E-
restricted T lymphocytes. In contrast, this HLA-E-peptide complex failed to activate 
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the inhibitory receptor NKG2A (Sensi et al., 2009). This suggests even the possibility 
of an anti-tumor immune mechanism exerted by HLA-E by presenting tumor-specific 
peptides to cytotoxic T lymphocytes, a mechanism which has not been proven yet. A 
role for HLA-E in regulating adaptive immunity in glioblastoma warrants further 
investigation.  
The overall role of HLA-E in glioblastoma biology still needs to be defined. The 
expression of HLA-E was elevated in pilocytic astrocytomas (WHO grade I) and 
glioblastoma (WHO grade IV) compared to gliomas of WHO grades II and III, but the 
expression of HLA-E was not associated with patient survival (Mittelbronn et al., 
2007). In contrast, another recent report describes a counter-intuitive positive 
prognostic correlation of HLA-E expression in human glioblastomas ex vivo with 
survival (Kren et al., 2011), a finding which might be related to subsequent therapies 
following tumor resection. However, in other tumor entities like breast (de Kruijf et al., 
2010) or colorectal cancer (Levy et al., 2008), enhanced expression levels of HLA-E 
were correlated with reduced survival. To elucidate the role of HLA-E in glioblastoma 
it might be promising to investigate HLA-E expression on cell subtypes within 
gliomas, like tumor infiltrating microglia (Kren et al., 2010). In this regard, the role of 
HLA-E expression on GIC in vivo for the survival of the patients warrants further 
investigation. 
The expression of MHC class-I molecules and therefore the immune recognition by 
CD8+ T cells are diminuished in gliomas as one mechanism of immune escape 
(Facoetti et al., 2005). In turn, reduced MHC class-I expression would lead to 
enhanced immune recognition by NK cells. IFN-γ is often used to enhance MHC 
class-I expression. In turn, in several tumor entities like leukemia, ovarian cancer or 
melanoma, HLA-E is upregulated on the cell surface upon treatment with IFN-γ 
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(Derre et al., 2006; Malmberg et al., 2002; Nguyen et al., 2009) which might protect 
these tumor cells from immune effector cell-mediated lysis. 
Here, we demonstrate the upregulation of HLA-E on a transcriptional level and on the 
cell surface following treatment with IFN-γ in glioblastoma cells (Figure 4A and B). 
However, IFN-γ exerts multiple effects in glioblastoma cells including the up-
regulation of MHC class-I and –II and co-stimulatory molecules, but also glioma the 
reduction of proliferation and invasion (Haque et al., 2007; Kane and Yang, 2010). In 
contrast, the upregulation of atypical MHC class-I molecules HLA-E and HLA-G 
(Wischhusen et al., 2007) and other immunosuppressive molecules like B7-H1 (Han 
et al., 2009) upon treatment with IFN-γ may serve as one further immune escape 
mechanism of glioblastoma cells. Having multiple, in part antidromic actions in glioma 
cells, the net effect of IFN-γ on the immunophenotype of GIC is crucial and might 
vary between patients. This is exemplified in Figure 4 with reduced (Figure 4C) or 
unchanged (Figure 4D) immunogenicity in GS-5 and GS-7 respectively upon 
treatment with IFN-γ. Therefore, the use of IFN-γ to boost an immune response 
against GIC might be limited.  
In this work, we used a panel of well characterized GIC lines, kept under stem cell 
culture conditions. Although controversially discussed (Beier and Beier, 2011; 
Tabatabai and Weller, 2011), CD133 is still used as a putative cell surface marker for 
GIC. Therefore, we assessed the role of HLA-E specifically on CD133+ cells 
exemplarily in the GIC line GS-2. The expression level of HLA-E was similar in 
CD133+ and CD133- GS-2 cells (Figure 5A). The siRNA-mediated silencing of HLA-
E expression enhanced NK cell-mediated immune recognition of CD133+ and 
CD133- GS-2 cells in a similar manner (Figure 5B). Together with the demonstration 
of enhanced expression of HLA-E on the surface of CD133+ cells upon treatment 
with IFN-γ, we thus reproduce the findings for the role of HLA-E in GIC lines in cells 
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sorted for the presence of CD133. Overall, HLA-E contributes to the 
immunosuppressive properties of GIC, but has to be considered in the context of a 
complex network of immune regulatory influences exerted by these cells. 
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6. Figure legends 
 
Fig. 1: Culturing of GIC. The GIC lines (as examples GS-4, GS-5 and GS-9) were 
cultured in stem cell-permissive neurobasal medium containing FGF-2, EGF, B27 
supplement and heparin. The scale bars are shown in the lower right corner. 
 
Fig. 2: HLA-E is differentially expressed under stem cell culture and serum-
containing conditions. 
HLA-E mRNA expression was analyzed by real-time PCR under stem cell culture (A, 
open bars) or differentiated conditions (B, GS-Xd, black bars). Data are expressed 
relative to GAPDH expression. One representative experiment is shown (n=2). (B-D) 
GIC and differentiated cultures were stained with mAbs for HLA-E (B and D; clone 
3D12), MHC-I (C; clone W6/32) or isotype-matched Ig, followed by staining with a 
PE-labelled anti-mouse secondary antibody. In B and C data represent mean SFI 
values ± SEM from 3 independent experiments (* p<0.05; student`s two tailed t-test). 
In (D) SFI values are indicated in the upper right corner and are representative of 
three independent experiments (curve in light grey: isotype control, dark grey specific 
mAb). 
 
Fig. 3: HLA-E gene silencing enhances susceptibility of GIC to NK cell-mediated 
lysis.  
(A) The GIC lines GS-2, GS-5 and GS-7 were transfected with control (siCtrl) or 
siRNA targeting HLA-E (siHLA-E). The cells were harvested 36 h later and knock-
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down efficiency was confirmed by flow cytometry (curve in light grey: isotype control, 
dark grey: specific HLA-E mAb, clone 3D12).  
(B) The cells transiently transfected with siCtrl or siHLA-E were used as targets in 
a cytotoxicity assay using NKL cells as effectors. Target cells were stained with the 
membrane dye PKH-26 and then co-cultured with NKL cells at various effector to 
target (E:T) ratios for 3 h in duplicates. The cells were stained with the viability 
marker ToPro3 to identify the lysed cells by flow cytometry. Specific lysis was 
calculated by substraction of background lysis from the fraction of dead cells. One 
representative experiment is shown (n=2 to 3).  
 
Fig. 4: The expression of HLA-E on GIC cell surface is enhanced by IFN-γ. 
GIC and corresponding differentiated cell cultures were incubated with IFN-γ (500 
IU/ml) for 48 h. (A) HLA-E mRNA expression was analyzed by real-time PCR. Data 
are expressed relative to GAPDH expression. One representative experiment is 
shown (n=2). 
(A) GIC and corresponding differentiated cell cultures were stained with mAbs for 
HLA-E (B; clone 3D12), MHC-I (C; clone W6/32) or isotype-matched Ig, followed by 
staining with a PE-labelled anti-mouse secondary antibody. Data represent SFI mean 
values ± SEM from 3 independent experiments (* p<0.05; student`s two tailed t-test). 
(C), (D) The GIC cell lines GS-5 and GS-7 were used as target cells in a cytotoxicity 
assay with NKL cells as effectors after stimulation with IFN-γ as described above. 
One representative experiment is shown (n=3) 
 
Fig. 5: NK cell-mediated lysis of GS-2 cells is independent of CD133 expression. 
(A) HLA-E cell surface expression on GS-2 GIC was assessed by flow cytometry 
following staining with anti-HLA-E (APC) and anti-CD133 (PE) or suitable isotype 
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controls. SFI values for HLA-E expression on cells gated for the presence or absence 
of CD133 are indicated in the upper right corner of the histograms which are 
representative of 2 independent experiments (curve in light grey: isotype control, dark 
grey: specific mAb; FSC: forward scatter). (B) Following FACS sorting of GS-2 cells 
for the presence or absence of CD133 cell surface expression, the cells were 
transfected with control (siCtrl) or siRNA targeting HLA-E (siHLA-E) and used as 
targets in a cytotoxicity assay using NKL cells as effectors as described above. One 
representative experiment is shown (n=2).  
 
